Skip to main content
. 2017 Nov 11;8(64):107907–107919. doi: 10.18632/oncotarget.22392

Figure 5. Down-regulation of YAP1 decreased holoclone-, sphere-forming capacity and invasive capacity in small CRC cells.

Figure 5

(A-B) Expression of YAP1 in large and small LoVo, HT-29 cells was detected by western blotting (A) and RT-qPCR (B). GAPDH was used as a loading control. Data are presented from triple experiments. (C) Knockdown of YAP1 in LoVo, HT-29 cells was measured by western blotting. GAPDH was used as a loading control. Data are presented from triple experiments. (D-E) Clonal culture for large and small LoVo (D), HT-29 (E) cells upon knocking down of YAP1. (L denotes large CRC cells, S denotes small CRC cells). Data are presented from triple experiments. (F-G) Sphere formation assay for large and small LoVo (F), HT-29 (G) cells upon knocking down of YAP1. Data are presented from triple experiments. (H-I) Tumor transplantation for large and small LoVo (H), HT-29 (I) cells upon knocking down of YAP1. Shown are tumor weights and incidence. Mean ± SD, *P< 0.05, **P< 0.01, ***P< 0.001.